CD8A and cancer: Nevertheless, potential safety concerns for some of these vaccine models, especially for immunocompromised individuals, and the overall weak CD8+ CTL-mediated immunity-remain major challenges in developing a safe and effective vaccine against HPV-associated malignancies [54–56].